The exponential rise in the number of cancer patients across the world and the concurrent rise in demand for nutrient supplements for combating cancer is driving the global market for cancer cachexia, finds an intelligence study by Transparency Market Research (TMR). The study is titled “Cancer Cachexia Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016–2024.”
It notes that although developed economies such as the U.S. and Europe presently dominate the market for cancer cachexia, the demand will surge quickly in emerging economies in the region of Asia Pacific due to vast populations and developing healthcare infrastructure. Estimating the impact of all the driving as well as retraining factors, the report projects a healthy CAGR for the market for cancer cachexia over the forecast period.
Download the — Industry Fact Sheet by 2024
Cachexia relates to a clinical condition that results in the buildup of liver proteins and depleting essential amino acids in the body. Cachexia also makes the patients prone to infections and reduces their ability to negotiate toxic effects of cancer therapies. The report observes that approximately 80.0% of advanced cancer patients suffer from cachexia, resulting in the death of up to 20% of the cases.
There are three stages to cachexia, namely pre-cachexia, cachexia, and refractory cachexia. The stage wherein patients lose muscles mass despite maintaining the overall body weight is called pre-cachexia. The stage of prominent and uncontrolled weight loss and muscle depletion is termed as cachexia. This stage can be controlled with the help of health supplements. In refractory cachexia, patients regain negligible weight that was lost and the symptoms of nausea and tiredness can be reduced.
According to the TMR report, there is still no therapeutic agent approved for the treatment of cachexia. While two classes of drugs, progestins and steroids, are commonly used off-label, the demand for novel and low-cost medicines is on the rise. Developed regions across the globe are raising the demand for novel drugs while cost-effective markets in Asia Pacific are pushing for affordable alternatives.
As a result, various prominent players in the pharmaceutical market are in the process of developing new vaccines and drugs to meet the unmet global demand. A few of the pipelined drugs in the cancer cachexia market are anamorelin, bimagrumab, hydrochloride, enobosarm, and dronabinol.
Conversely, the lack of approved therapeutics in the cancer cachexia market is one of the prominent restraints that has been studied in the report, and its impact on the overall growth of the market has been evaluated.
Some of the key players in the cancer cachexia market are Aphios Corporation, Alder Biopharmaceuticals Inc., Aeterna Zentaris Inc., XBiotech USA, Inc., Itis Pharmaceuticals Pty Ltd, Helsinn Healthcare S.A., and Novartis AG.